Derms on Drugs is where cutting-edge dermatology meets mediocre comedy. Each week three dermatologists – Matt Zirwas, Laura Ferris and Tim Patton – discuss, debate, and dissect the hottest topics in dermatology. It's everything you need to know to be on the cutting-edge of dermatology and it’ll be the most fun you’ve ever had while actually learning something useful. Derms on Drugs is produced by Scholars in Medicine, an online educational platform (scholarsinmedicine.com) exclusively for healthcare professionals of all levels of experience and education.
The EADV meeting showcased several emerging therapeutic advancements in dermatology, focusing on novel mechanisms for complex conditions. Intralesional BO112, a double-stranded RNA nanoparticle, demonstrated potential in treating basal cell carcinoma by stimulating innate immune responses. For hidradenitis suppurativa,...
Chronic Spontaneous Urticaria (CSU) management requires selecting between remibrutinib, omalizumab, and dupilumab. Dr. Jason Hawkes advocates for remibrutinib as a first-line therapy, emphasizing its rapid onset of action and direct mechanism targeting mast cell degranulation, which effectively addresses both IgE-depen...
Clinical research in dermatology highlights novel therapeutic approaches and evolving diagnostic challenges. High-dose oral vitamin D supplementation, ranging from 100,000 to 200,000 IU, offers a safe, low-cost intervention for managing toxic erythema of chemotherapy and radiation dermatitis by potentially modulating i...
Recent advancements in dermatology focus on combination therapies and personalized medicine. The mRNA melanoma vaccine, specifically the Keynote 942 study, demonstrates improved recurrence-free survival when combined with pembrolizumab, though recent phase 3 press releases lack detailed peer-reviewed data. Hidradenitis...
Nolla has launched an AI-driven telemedicine platform in Utah that allows for the autonomous initiation of acne treatment plans without a human provider present. By analyzing patient-submitted photos and medical histories, the system provides tailored topical prescriptions, achieving a 96% agreement rate with human cli...
Cosentyx serves as an optimal first-line systemic treatment for Hidradenitis Suppurativa (HS) due to its superior durability and lower risk of neutralizing antibodies compared to TNF-alpha inhibitors. While IL-17 blockade provides consistent inflammatory control, TNF-alpha inhibitors remain a preferred alternative for ...
Exosomes hold significant potential for tissue repair and regeneration, yet current commercial aesthetic products often lack scientific validation and regulatory oversight. Dr. Van Bariavis, a dermatologist and scientist at the University of Miami, explains that while mesenchymal stem cell-derived vesicles can facilita...
The 2025 Antibiotic Prophylaxis in Dermatologic Surgery (APDSAS) advisory statement simplifies clinical practice by restricting prophylaxis to mucosal or infected skin procedures, effectively removing previous requirements for groin or lower-extremity second-intent healing. Regarding atopic dermatitis, treatment persis...
Chronic Spontaneous Urticaria (CSU) requires a diagnosis of exclusion primarily based on clinical history rather than routine laboratory testing. Dr. Marc Serota, a specialist in pediatrics, dermatology, and allergy, emphasizes that for classic cases, immediate treatment is more effective than extensive workups. Labora...
Inpatient teledermatology bridges the critical gap in dermatological care for the vast majority of U.S. hospitals lacking on-site specialists. By utilizing asynchronous store-and-forward technology, dermatologists can provide expert management recommendations, significantly reducing diagnostic discordance and unnecessa...
The RESOLVE-AD trial for moderate-to-severe atopic dermatitis introduces respegaldesleucin, an IL-2 receptor agonist designed to restore immune homeostasis by expanding regulatory T cells. While the drug shows a 61% mean reduction in EASI scores, concerns persist regarding its long-term safety and the potential for mal...
Early systemic intervention for Hidradenitis Suppurativa (HS) prevents irreversible structural damage, such as tunneling and scarring, which significantly diminishes long-term quality of life. Dr. Chris Sayed emphasizes that waiting for advanced disease stages lowers the potential for achieving high-level clinical resp...
Managing undifferentiated dermatitis requires balancing clinical intuition with practical diagnostic strategies. While some advocate for a "clear, patch test, avoid, treat" protocol to identify specific allergens before initiating systemic therapies like dupilumab, others argue that immediate systemic intervention is o...
Hidradenitis suppurativa (HS) treatment and melanoma management protocols dominate this clinical discussion. Povercitinib, an oral JAK1 inhibitor, demonstrates statistically significant efficacy in phase 3 trials for HS, showing improved outcomes over 54 weeks despite a modest separation from placebo and manageable saf...
Male genital disease, specifically lichen sclerosus and its progression to penile cancer, requires a shift in clinical perspective. Lichen sclerosus is a clinical diagnosis caused by chronic exposure to urine in uncircumcised men rather than an autoimmune process. Management involves ultra-potent topical steroids and b...
Tofacitinib has emerged as a cost-effective, off-label treatment option for refractory dermatologic conditions, though its safety profile requires nuanced clinical judgment. Data from the Oral Surveillance trial in rheumatoid arthritis patients indicates elevated risks for major adverse cardiovascular events (MACE), ma...
Pediatric dermatology has evolved significantly with the introduction of new topical treatments for atopic dermatitis, including Opzelura, Zoryve, and Vtama. These agents offer improved efficacy and tolerability compared to traditional steroids and calcineurin inhibitors, though clinicians must carefully balance potenc...
Chronic Spontaneous Urticaria (CSU) management has evolved significantly, with international guidelines now positioning omalizumab, remibrutinib, and dupilumab as primary treatment options alongside antihistamines. Extensive diagnostic testing for CSU is largely redundant, as results rarely alter clinical management; p...
Image-Guided Superficial Radiation Therapy (IGSRT) for non-melanoma skin cancer costs significantly more than Mohs micrographic surgery, prompting recent Medicare coding restrictions to limit medically unnecessary ultrasound simulations. Beyond surgical costs, clinical research identifies "satellite nevi"—moles located...
Managing challenging nail conditions requires a high index of suspicion, particularly for longitudinal melanonychia in adults, where a single pigmented nail necessitates investigation to exclude melanoma. Biopsy procedures, such as matrix shaves or punches, should target the origin of the pigment, while monitoring for ...
Follow this podcast in Podwise
Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.
